Regular follow-up of patients with NF1 is recommended because of theincreased risk of neoplasms, such as optic nerve gliomas, glioblastomas, malignanttumors of peripheral nerves, pheochromocytomas, gastrointestinal stromal tumors, andcarcinoid tumors of the duodenum, as well as breast cancer, leukemia, andrhabdomyosarcoma(1). This evidence concerns the gene NF1 and neoplasm.